ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0965

Anti-TNF Usage in Patients with HIV Infection 2003-2021: Long Term Safety and Followup

Benjamin Naovarat1, Francis Williams2, Gloria Salazar3 and John Reveille4, 1University of Texas McGovern Medical School, Houston, TX, 2Specialists for Health/Wellmed, Shavano Park, TX, 3University of Texas Medical School at Houston/McGovern Medical School, Houston, TX, 4Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX

Meeting: ACR Convergence 2021

Keywords: Anti-TNF Drugs, Infection, prognostic factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Abstracts: Infection-related Rheumatic Disease (0962–0965)

Session Type: Abstract Session

Session Time: 11:15AM-11:30AM

Background/Purpose: There are concerns about using immunosuppressive agents for treatment of rheumatic diseases in patients with HIV infection due to concerns of opportunistic infection. We previously reported a series of eight HIV positive patients primarily seen at a County Outpatient Rheumatology Clinic treated with anti-TNF agents between 2003 and 2008 (Cepeda et al, Ann Rheum Dis 67: 710-12, 2008). The purpose of this study is to report the safety and efficacy of anti-TNF agents in these patients over time to the present and to update our experience with biologic agents in this setting in additional patients.

Methods: All but three of the patients were seen at the Harris County HIV Outpatient Clinic. At baseline visit, sociodemographic characteristics, CD4 counts, HIV viral load and medications were collected. Patients with rheumatoid arthritis or spondyloarthritis were initially treated with NSAIDs and nonbiologic disease modifying antirheumatic drugs(DMARDs) (methotrexate, sulfasalazine) and intra-articular/intralesional corticosteroids. Those patients with persistent disease activity despite conservative therapy were begun on anti-TNF agents, provided CD4 counts were above 200 cells/μl and HIV viral load < 60,000 copies/ml (as per guidelines for use of immunosuppressive agents in the face of HIV infection).

Results: In total, 18 patients were treated with anti-TNF agents, including 8 treated with anti-TNF agents between 2003 and 2006 (two RA, two peripheral spondyloarthritis (SpA), of whom we have follow-up data on seven, and an additional nine treated with anti-TNF agents since then. There were no major infectious episodes that necessitated discontinuation of the medications, although one patient seen after 2006 had his adalimumab discontinued by his primary care doctor because of rising HIV viral load. The data on seven of the original eight are shown in Table 1 (one patient was seen only transiently in 2004 and was lost to followup).Of these original seven patients, four are still currently followed (of whom one is on adalimumab and one ustekinumab, the other two in remission) and all seven have been seen in the past six years. Of the nine patients begun on anti-TNF agents since 2006, all but one are currently being followed. by us, of whom six are still taking anti-TNF agents. Three had discontinued them, one due to lack of efficacy, one because of a rising HIV viral load, and one due to fears of toxicity(though no actual event was recorded)..

Conclusion: In this series of 17 HIV positive patients, followed up to 18 years, the largest and longest followed reported to date, our data underscore the safety of using anti-TNF agents in patients with HIV infection over long duration, provided standard precautions of using immunosuppressive agents in the setting of HIV infection are followed.

Table 1. Clinical, Sociodemographic and Current Status of Initial Seven HIV Patients Treated with Anti-TNF Agents 2003_2006

Table 2. Clinical and Sociodemographic Features of HIV Patients with Rheumatic Disease Treated with Anti-TNF Agents after 2006.


Disclosures: B. Naovarat, None; F. Williams, None; G. Salazar, None; J. Reveille, UCB, 1, Eli Lilly, 1, Eli Lilly, 5, Novartis, 1.

To cite this abstract in AMA style:

Naovarat B, Williams F, Salazar G, Reveille J. Anti-TNF Usage in Patients with HIV Infection 2003-2021: Long Term Safety and Followup [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/anti-tnf-usage-in-patients-with-hiv-infection-2003-2021-long-term-safety-and-followup/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-tnf-usage-in-patients-with-hiv-infection-2003-2021-long-term-safety-and-followup/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology